Abstract Background: Breast cancer is the most common malignancy in Uruguay, with approximately 75% of women treated for this disease receiving adjuvant radiotherapy. Radiation-induced skin toxicity (radiodermatitis) significantly impacts treatment tolerance, yet no robust evidence supports a single standard topical treatment to mitigate these adverse effects. This study aims to evaluate whether a topical cream containing 5% panthenol and Centella asiatica extract can effectively reduce radiodermatitis compared to standard care in breast cancer patients undergoing radiotherapy. Methodology: This prospective, randomized, open-label clinical trial will be conducted at Hospital de Clínicas Dr. Manuel Quintela in Uruguay. Eighty patients with breast cancer requiring adjuvant radiotherapy using hypofractionated schemes (240-340 cGy per fraction) will be randomized in a 1:1 ratio to receive either: daily water washing plus twice-daily application of a cream containing Centella asiatica extract and 5% panthenol (Group A), or daily water washing alone (Group B). Weekly clinical evaluations during treatment will be performed by radiation oncologists using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Consenting patients will also have photographic documentation evaluated by an independent, blinded dermatologist. The primary endpoint is radiodermatitis-free time measured in days. Secondary endpoints include the proportion of patients experiencing radiodermatitis of any grade and the proportion developing grade ≥2 radiodermatitis. Statistical analysis will use Kaplan-Meier survival curves with log-rank tests for univariate analysis and Cox regression for multivariate analysis, using SPSS version 29.0. Sample size was calculated to detect a 12-day difference in radiodermatitis onset with 80% power and significance level of 0.05. Expected outcomes: This study will determine whether a cream containing 5% panthenol and Centella asiatica extract can delay radiodermatitis onset and reduce its incidence during breast radiotherapy. The results will provide more the needed evidence to standardize skin care protocols in radiotherapy, potentially improving treatment tolerance and quality of life for breast cancer patients undergoing radiotherapy. Registration: This study has been registered with the Uruguayan Ministry of Public Health (Registration number: 9170979, registered April 21, 2025). Citation Format: J. C. Ferrer, S. Guerreros, M. Torres, M. Vola, E. Rivero, L. Ricagni, A. Notejane, M. Giordano, P. Fernandez, S. Roldan, F. Lorenzo. Use of cream with 5% panthenol and Centella asiatica extract in patients undergoing breast radiotherapy: a randomized study in Uruguay abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-07-29.
Ferrer et al. (Tue,) studied this question.